Dlamini Zodwa, Mbita Zukile, Ledwaba Thokozile
University of the Witwatersrand, School of Molecular and Cell Biology, Genetics and Developmental Biology Division, P/Bag 3, Johannesburg, 2050, South Africa.
Future Oncol. 2005 Jun;1(3):339-49. doi: 10.1517/14796694.1.3.339.
A defect in apoptosis is almost always linked to many pathologies, including cancer. Carcinogenesis has been linked to abnormalities in the apoptotic pathway, and many drugs that are targeted at different parts of this pathway are being developed. There have been many promising drugs that target the extrinsic death receptor pathway as well as the intrinsic mitochondrial apoptotic pathway. There have also been developments in targeting initiator and effector caspases, as well as the death domains that are involved in transducing the apoptotic signals. In this review, the authors will briefly explain how apoptosis deregulation can lead to cancer and discuss drugs that promise success in targeting this anomaly. This article shall also explain how co-treatments with chemotherapy can increase survival of cancer patients. There is a problem of acquired resistance in some of these therapies but there may be ways to overcome this.
细胞凋亡缺陷几乎总是与包括癌症在内的多种病理状况相关联。肿瘤发生与凋亡途径的异常有关，并且许多针对该途径不同部位的药物正在研发中。已经有许多有前景的药物靶向细胞外死亡受体途径以及细胞内线粒体凋亡途径。在靶向起始和效应半胱天冬酶以及参与转导凋亡信号的死亡结构域方面也有进展。在这篇综述中，作者将简要解释细胞凋亡失调如何导致癌症，并讨论有望成功靶向这种异常的药物。本文还将解释联合化疗如何提高癌症患者的生存率。这些疗法中存在一些获得性耐药问题，但可能有克服这一问题的方法。
